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REVIEW
The blind men and the AML elephant: can we feel the
progress?
S Tauro
The pharmacological therapy of non-promyelocytic acute myeloid leukemia (AML) has remained unchanged for over 40 years with
an anthracycline–cytarabine combination forming the backbone of induction treatments. Nevertheless, the survival of younger
patients has increased due to improved management of the toxicity of therapies including stem cell transplantation. Older patients
and those with inﬁrmity that precludes treatment-intensiﬁcation have, however, not beneﬁted from improvements in supportive
care and continue to experience poor outcomes. An increased understanding of the genomic heterogeneity of AML raises the
possibility of treatment-stratiﬁcation to improve prognosis. Thus, efforts to identify agents with non-conventional anti-leukemic
effects have paralleled those aiming to optimize leukemia cell-kill with conventional chemotherapy, resulting in a number of
randomized controlled trials (RCT). In the last 18 months, RCTs investigating the effects of vosaroxin, azacitidine and gemtuzumab
ozogamycin and daunorubicin dose have been reported with some studies indicating a statistically signiﬁcant survival beneﬁt with
the investigational agent compared with standard therapy and potentially, a new era in AML therapeutics. Given the increasing
costs of cancer care, a review of these studies, with particular attention to the magnitude of clinical beneﬁt with the newer agents
would be useful, especially for physicians treating patients in single-payer health systems.
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INTRODUCTION
In the year 2016, it is sobering to reﬂect that the pharmacological
treatment of most forms of acute myeloid leukemia (AML) has
remained unchanged over four decades. The relatively limited
therapeutic stratiﬁcation of AML owes more to serendipitous
interventions and observations than an enhanced understanding
of disease biology or pharmacodynamics.1,2 The improvement in
remission rates of non-acute promyelocytic leukemia AML
following induction chemotherapy too should be credited to
progress in supportive care and not novel anti-leukemic
strategies.3 Regrettably, most remissions remain short-lived,
impacting particularly on patients over 60 years of age, in whom
the disease is frequent and treatment-intensiﬁcation often
precluded by co-morbidity. Recent developments in the genomic
and functional characterization of AML4,5 along with the
availability of a plethora of novel therapeutic options including
small molecule drugs have promised much to improve outcomes
over conventional therapy.
Attempts to translate promising in vitro and early-phase clinical
studies of newer agents into routine hematology practice has
begun in earnest through phase 3 randomized controlled trials
(RCTs). Considered the gold standard to evaluate the effectiveness
of interventions, RCT can be practice-changing, but an enthusias-
tic analysis of ever-increasing numbers of measures in trials
lacking sufﬁcient power could make RCT a double-edged sword,
particularly in rarer diseases such as AML. Too often, data of
elephantine proportions from contemporary RCTs are accorded
the same dogmatic response as that from the proverbial blind
men in their description of the elephant. In the fable, with just the
powers of proprioception at their disposal to examine a limited
part of the elephant’s anatomy, the resulting irreconcilable
descriptions of the animal could almost have been predicted.
This study of the elephant would appear to be a truly blinded one
with no obvious external confounders contributing to the
conclusions; the ﬁnancial, human, intellectual and time invest-
ment in RCTs, combined with expectations from clinicians and
patients faced with a life-shortening illness and dearth of effective
treatments, means that the desire to identify the next poster child
in AML therapeutics is strong. RCTs reported recently thus appear
to herald the arrival of treatment strategies including novel drugs,
with the potential to improve survival in AML,6–9 but in the
interests of fairness to other ‘blind men’, particularly those based
in single-payer healthcare systems, a different perspective on the
same data set could be useful.
VOSAROXIN
The phase 3, double-blind, placebo controlled trial, VALOR,
randomized over 700 patients to investigate whether the addition
of the quinolone derivative vosaroxin to cytarabine improves
survival in relapsed or refractory AML.6 Unstratiﬁed analysis
showed no survival difference between the arms of the study.
Following adjustment for pre-randomization variables, a median
survival difference of ~ 2 months in favor of the vosaroxin arm was
observed, maintained in a predeﬁned analysis of patients over 60
years old. Based on these results, how meaningful an advance is
combination therapy with vosaroxin–cytarabine toward establish-
ing a new standard of care in poor-risk AML? While complete
remission (CR) in the vosaroxin arm was almost double that with
standard therapy (30 vs 16% respectively; Po0.0001), one cannot
help noticing that these ﬁgures appear inferior to those achieved
in a previous RCT of high-risk AML (MRC AML-HR) where the CR
rates approach 60%.10 These differences should nevertheless be
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interpreted with caution, given the heterogeneity in patient
demographics and disease, as well as disease deﬁnition criteria in
the two RCTs separated by a time-lapse of 10 years. When one
examines early-mortality rates between the two arms of VALOR,
these are undoubtedly similar. Worryingly, however, 80% of
participants had to discontinue therapy after the ﬁrst cycle (of an
intended total of four cycles) for reasons of treatment failure,
death or toxicity. That discontinuation rates in the experimental
arm containing vosaroxin were similar to the control provides
scant reassurance: if only 20% of the participants with a
performance status of ⩽ 2 at trial entry are capable of proceeding
with further therapy, then our deﬁnition of the ‘standard’ requires
re-evaluation. Based on the 1-year survival data in VALOR, 19
patients would need to be treated with cytarabine and vosaroxin
to prevent one death after ‘standard’ therapy. Had VALOR been
sufﬁciently powered for the survival beneﬁt of combination
therapy in the over-60 s sub-analysis to be conclusive, many
physicians in single-payer healthcare systems would still wonder
whether the anticipated quality-of-life and resource utilization for
a 2-month median survival beneﬁt is sufﬁcient for vosaroxin–
cytarabine to merit consideration as a cost-effective, new
standard.
AZACITIDINE
In contrast to vosaroxin, the hypomethylating nucleoside analog
azacitidine was manufactured in the 1960s, but its evaluation in
RCTs for patients with myeloid malignancies has been more
recent.7,11 In patients with intermediate-2 and high-risk myelo-
dysplastic syndromes (MDS) including chronic myelomonocytic
leukemia (CMML) and AML with a marrow blast count of 20–30%,
azacitidine has been shown to prolong survival by a median of
9.5 months over conventional care regimens (CCRs) including best
supportive care (BSC), low-dose (non-intensive) cytarabine or
intensive chemotherapy (hazard ratio 0.58, P = 0.0001).11 No
additional RCT has been undertaken to conﬁrm this result but in
conjunction with the manufacturer’s patient access schemes, in
the UK, azacitidine was considered a cost effective option to treat
sub-groups of MDS, including CMML and AML patients grouped
either through similarities of predicted clinical outcomes12 or of
morphological features. The results of a subsequent phase 2 study
indicating lack of signiﬁcant beneﬁt with azacitidine in CMML, as
well as the inability of mutational and methylation proﬁles to
stratify responses are therefore disappointing and highlight
unresolved challenges to the prospective identiﬁcation of patients
that would optimize cost-effectiveness of the drug.13
Nevertheless, the improvement in outcomes in low-blast count
AML patients treated with azacitidine11 mandated an investigation
of the drug in patients with a higher blast percentage.7 Conducted
over 18 countries, the AZA-AML-001 RCTs asked if azacitidine
compares favorably to CCR. As with the previous study in MDS/
AML,11 the selection of the CCR option (including BSC) for
randomization against azacitidine was left to the discretion of the
treating physicians, making the trial not completely randomized
and potentially open to bias. This design may have a pragmatic
basis: clinicians are known to be less enthusiastic about
randomizing patients between intensive and non-intensive
treatment,14 or older patients may be reluctant to participate to
a trial involving more intensive interventions of, as yet, unproven
beneﬁt. However, the grouping of heterogeneous therapies
known to alter patient outcomes15 under the umbrella of CCR
means that the ﬁnal analysis could have masked meaningful
differences in outcomes between the individual CCR options and
azacitidine. There are further confounding variables with the
potential to inﬂuence the results: standards for BSC have not been
explicitly deﬁned, so a role for variation in inter-institutional
clinical practice as a determinant of survival cannot be
excluded.16,17 Whether the frequency of contact between
healthcare professionals and patients differed between the study
arms to introduce bias also requires consideration.18 Unsurpris-
ingly perhaps, the study failed to meet its primary end point as
azacitidine therapy did not associate with a statistically signiﬁcant
improvement in overall survival. Through a series of sub-analysis,
many of which were pre-speciﬁed but underpowered, a survival
beneﬁt with azacitidine over BSC was identiﬁed. In another
comparison, the median survival until subsequent therapy (time to
next therapy (TTNT)) too favored azacitidine over CCR by almost
5 months (hazard ratio = 0.76, 95% conﬁdence interval, 0.60–0.96;
P= 0.019). The choice of TTNT as an end point is an interesting,
arguable one since its use should optimally be restricted to the
analysis of outcomes in diseases with effective, life-prolonging
sequential therapies19 unlike relapsed AML in the elderly, where
there are few meaningful therapeutic options. Moreover, there are
no prescribed criteria for specifying TTNT in AML, so the timing of
therapy is governed by clinical judgement, an easy source of bias.
An often-cited merit of hypomethylating therapy is its
perceived ability to improve survival in patients with poor-risk
cytogenetics,20–23 in whom low-dose cytarabine and intensive
chemotherapy are ineffective as primary therapy. Indeed, the sub-
analysis of patients with poor-risk karyotype in AZA-AML-001
lends further support to this perception, but the inadequate
power of the study fails to make the results more deﬁnitive.
Whether all elderly patients in whom performance status or co-
morbidity precludes intensive chemotherapy, or just those with a
poor-risk karyotype should receive azacitidine for an improvement
in outcomes thus remains an open question.
GEMTUZUMAB OZOGAMICIN
Despite investigation in multiple RCTs, few drugs have demon-
strated the capacity to divide opinions as much as Gemtuzumab
ozogamicin (GO).24–28 Accelerated approval by the Food and Drug
Administration (FDA) in 2000 for the therapy of relapsed AML in
older patients unsuitable for other intensive therapies29 was
followed by an amazing fall-from-grace with a follow-up SWOG
RCT, indicating not only lack of beneﬁt but also suggesting
increased mortality with GO.28 A confounding role for the
unexpectedly low mortality in the control group of the study, as
well as anthracycline dosage differences between the cohorts
continues to be debated, but the drug was voluntarily withdrawn
from the market by the manufacturer in 2010. In combination with
chemotherapy, GO has now been studied in further RCTs, some of
which indicate a reduction in relapse risk and improvement in
overall survival without increased toxicity.24,25,27 Meta-analyses of
RCTs too have yielded conﬂicting conclusions regarding a survival
beneﬁt.30,31 Patients in whom a consistent beneﬁt with GO can be
cautiously claimed through data from RCTs (including the SWOG
study28) and meta-analyses are those with favorable cytogenetics
with no apparent advantage to those with unfavorable
karyotype.30,31 Highlighting the polarization of opinion regarding
GO, the drug is included in all induction schedules for newly
diagnosed patients with good and intermediate cytogenetics in
the UK-based AML18 and AML19 RCTs.
Amidst this fervour, is a recent report on a randomized
comparison between GO and supportive care (including oral
chemotherapy with hydroxycarbamide or nucleotide analogs) in
AML patients unsuitable for intensive chemotherapy.9 Fractio-
nated doses of GO (9 mg m−2) were administered on day 1 and
day 8 as induction treatment, followed by 2 mg m−2 once a month
for further eight cycles. Of the patients who received induction
therapy, over half received at least one additional dose, with the
median number of infusions being 3. Patients receiving GO had an
assessment of disease response beginning at day +36 with just
under a quarter achieving a response (CR 8.1% and CR incomplete
16.2%). ‘Stable disease’ was observed in ~ 40% of patients
receiving GO; whether this is a valid, clinically meaningful end
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point in AML cannot be ascertained since no data from the
supportive care arm were provided. With the median survival in
both groups being o6 months, a survival beneﬁt of 1.3 months
was observed in favor of GO (hazard ratio, 0.69; 95% conﬁdence
interval, 0.53 to 0.90; P= 0.005), in the absence of a signiﬁcant
increase in toxicity particularly to the liver. Thus, while single-
agent GO has demonstrable anti-leukemic effects and tolerability
in patients ineligible for intensive chemotherapy, its cost-
effectiveness over low-dose cytarabine associated with similar
responses15 requires evaluation. The median time to CR/CR
incomplete with GO (36.5 days, range 14–139)9 appears faster
than with low-dose cytarabine (CR time 114 days, range 50–313)15
but comparative data on quality-of-life and resource utilization
through a randomized trial of the two drugs do not currently exist.
Attempts to augment the anti-leukemic effects of therapy with
combination low-dose cytarabine and GO include RCTs in patients
unsuitable for more intensive approaches, but despite a near-
doubling of response rates with combination therapy compared
with low-dose cytarabine there was no discernible survival
advantage.32 Resource utilization (platelet and antibiotic support
and in-patient care) was higher with combination therapy and the
absence of quality-of-life data in patients achieving CR means that
the global impact of achieving higher remission rates is uncertain.
For these reasons, the status of low-dose cytarabine as the
therapeutic standard for elderly or inﬁrm AML patients remains
unchallenged.
HIGH-DOSE DAUNORUBICIN
The quandary of the blind men with the pachyderm is well-illustrated
not just in the interpretation of RCTs involving newer agents, but also
in the evaluation of conventional chemotherapeutic dosage in newly
diagnosed patients.8,33,34 Since most contemporary clinical studies in
AML include drugs purportedly targeting leukemic cells, the
assumption that half-a-century’s experience with genotoxic che-
motherapy would have optimized induction schedules for AML
therapy is a reasonable one. However, results from recent studies on
outcomes following higher doses of daunorubicin (90 mgm−2)
compared with 45 mgm−2 or 60 mgm−2 during induction treatment
with cyatarbine suggest otherwise,8,33,34 and indicate that adages
from 1973 continue to be relevant in 2016. Indeed, ‘daunorubicin is
obviously a difﬁcult drug to handle since in an empiric way there is a
narrow dosage range and schedule which will induce an optimal
aplasia, destroying proliferating leukemia cells but sparing stem
cells’.35
In an RCT involving 582 patients conducted by the Eastern
Cooperative Oncology Group (ECOG) ﬁrst reported in 2010,33 and
recently updated,34 the CR rate with higher-dose daunorubicin
(71%) was superior to that (57%) with a 45 mg m−2 dose and
translated into a signiﬁcant improvement in overall survival.
However, using induction schedules containing 50 mg m−2
daunorubicin, the UK-based MRC trials had previously demon-
strated outcomes that were comparable to those achieved with
higher-dose daunorubicin.36 A randomized comparison of higher-
dose daunorubicin with 60 mg m−2 was therefore undertaken in
1206 patients in the AML-17 study: although the follow-up period
was relatively short, this failed to demonstrate the beneﬁts with
90 mg m−2 over 60 mg m−2 daunorubicin either in CR rates or
longer-term survival, but suggested increased mortality at 60 days
with higher-dose daunorubicin.8 Could one therefore conclude
that induction regimens containing 90 mg m−2 daunorubicin are
superior to 45 mg m−2 but not 60 mg m−2 thereby establishing
60 mg m−2 as the standard of care? Attempts to address this
question require comment on the design and drug dosage
schedules of the two RCTs: induction therapy in the ECOG
schedule involved administration of daunorubicin on 3 consecu-
tive days and continuous infusion of cytarabine (100 mg m−2
per day for 7 days),33,34 whereas in AML-17 a more ‘staggered’
schedule of daunorubicin (days 1, 3 and 5) and cytarabine
(200 mg m−2 per day in divided doses 12 h apart, for 10 days) was
followed. Furthermore, in the North American study3,33,34 only
patients not achieving clearance of blasts in a ‘nadir’ biopsy
following 12–14 days of therapy received additional doses of
daunorubicin. In contrast, in the MRC study assessment of disease
response occurred at a later stage (days 21–25), with most
patients receiving a second daunorubicin-containing induction
cycle (50 mg m−2 days 1, 3 and 5). Thus, the cumulative doses of
daunorubicin administered to patients in CR who continued with
this study (330 mg m−2 and 420 mg m−2 in each arm, respectively)
exceeded that in the SWOG study, where over 90% of participants
in remission received a total dosage of ⩽ 270 mg m−2. Only a
minority of patients (o10%) within the higher-dose arm in the
SWOG study, requiring two cycles of induction to attain CR,
received 405 mg m−2 daunorubicin. Hence, the total daunorubicin
exposure for a larger proportion of SWOG participants (including
most in the ‘higher-dose’ arm) was less than in the MRC study.
Further differences that confound a direct comparison of the two
studies include the provision of cytokine support, risk-stratiﬁcation
criteria and choice of consolidation therapy. It is therefore highly
likely that in the foreseeable future, geographical location will
continue to determine the design of induction schedules and
doses of daunorubicin for newly diagnosed patients with AML.
There is no doubt that the RCTs reviewed here ask pertinent
questions in areas of unmet medical need.6–9 These multi-centric
international trials demonstrate clearly, the desire among
investigators to evaluate a hypothesis of interest despite the
potential for logistical difﬁculties and variation in legislation
relevant to research governance in different countries. As with all
good science, however, the evidence requires to be examined
more forensically before a transition to routine clinical practice can
occur. In an era when new drugs are increasingly being priced
high, it is no longer appropriate to focus the appraisal of newer
agents or interventions exclusively to a statistically valid, clinical
end point.37,38 A health technology assessment (http://www.nets.
nihr.ac.uk/programmes/hta) that incorporates the magnitude of
beneﬁt, along with social and ethical considerations is now
indispensable for establishing cost-effectiveness, and to avoid any
misplaced ‘shroud-waving’ arising from negative decisions on
funding of new technologies. The debate about anti-neoplastic
drugs is more emotive than the therapy for many chronic diseases
since there is a dearth of suitable therapies for many cancers and
continuing concern surrounding the affordability of proven, life-
prolonging drugs.39 To apportion all blame to the pharmaceutical
industry for the spiraling costs of healthcare, however, would be
inappropriate; while most physicians may be unaware of the
nuances of health economic modeling, they have a responsibility
to inform the cost-beneﬁt dialog around novel treatments by
identifying progress that is clinically, and not just statistically
meaningful. With the recently described newer pharmacological
agents and therapeutic strategies,6–9 subsets of AML patients
could experience an improvement in outcomes. As one waits
impatiently for the scientiﬁc tools to specify these subsets
prospectively, the premature adoption of newer treatments for
managing all patients with AML, could be counter-productive.
Rather than viewing the opinions expressed here as the ‘pouring
of cold water’ on novel data by another ‘blind man’, this
perspective should be considered as contributory to the recently
published data sets. After all, had the blind men in the fable
adopted a collaborative, non-dogmatic approach, it might have
been possible to reach a fairly sound description of the elephant.40
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